A Crystallographically Characterized Nine-Coordinate Calcium−Phosphocitrate Complex as Calcification Inhibitor in Vivo

Demadis, Konstantinos D.; Sallis, John D.; Raptis, Raphael G.; Baran, Peter

doi:10.1021/ja016384q

Cited by 41 publications

(36 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This may be explained on the basis that there is an optimum ingested amount above which no further increase in biological fluid concentrations can be achieved, and this was not affected by the type of InsP 6 salt used (calciummagnesium or sodium) (Grases et al, 2000b(Grases et al, , 2001c. Employing the same model to study the effects of phosphocitrate (a crystallization inhibitor) on dystrophic calcifications in vivo, Demadis et al (2001) reported important reductions in plaque formation. In that study the inhibitor was administered by intraperitoneal injections on alternate days.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

et al. 2004

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

“…), and whole blood removed and the developed plaques excised and weighed. Previous work had established a direct relationship between plaque weight and precipitation of hydroxyapatite (Cooper and Sallis, 1993;Demadis et al, 2001). Animal weights were monitored on days 1, 4, 12, 17, 25 and 31 during the study.…”

Section: Animals Diets and Experimental Designmentioning

confidence: 99%

Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

et al. 2004

View full text Add to dashboard Cite

“…The protection mechanism of PC's action is not clear but it could be as a result of PC binding to the membrane by virtue of its charge or simply not allowing crystals to penetrate it. It is important to point out that PC has never been observed to provoke any toxicity to animals or cells at any of the concentrations used [10,23,26,34]. This is perhaps not surprising given that it exists in mammalian mitochondria.…”

Section: Previous and Present Research With Pcmentioning

confidence: 89%

“…A new salt, a CaNaPC form has been developed [10] which, in limited studies, has raised the possibility that in defined situations it can be more potent than its parent PC [10,11]. The exact chemical formula of this form of PC is "CaNa(PC) 2 (H 2 O)".…”

Section: Phosphocitrate(s) Chemistrymentioning

confidence: 99%

Phosphocitrate, A Potential Therapeutic Agent for Calcium Crystal Deposition Diseases

Sallis¹,

Demadis²,

Cheung³

2006

CRR

View full text Add to dashboard Cite

The deposition of calcium-containing crystals in articular tissues is probably an under-recognized event.Clinical observations indicate that exaggerated and uniquely distributed cartilage degeneration is associated with these deposits. Perhaps the most compelling argument favoring a role for crystals in Osteoarthritis (OA) stems from their in vitro effects on articular tissues. Therapeutic options are limited and of compromised value for controlling and/or eliminating calcium crystal salt diseases. This review highlights past and present studies related to phosphocitrate (PC), a relatively unheralded compound with an ability to inhibit crystal nucleation, growth and aggregation of calcium salts, including basic calcium phosphate (a term including carbonate-substitute apatite, octacalcium phosphate, and tricalcium phosphate) and calcium pyrophosphate dihydrate. In addition, cell culture studies reveal that specific calcium phosphateinduced cellular events associated with osteoarthritis also are retarded by PC. Interest in the tetra-sodium PC form and the new Calcium/Sodium/PC (CaNaPC) salt has stemmed from their chemical characteristics and biological actions. In two instances, the CaNaPC has displayed superior inhibitory properties to that of the tetra-sodium salt. Using a calcergy animal model, a chemically-induced calcifying skin plaque in rats has been ameliorated while in cell culture studies, strong inhibition of calcium phosphate-DNA co-precipitates induced cell death has been noted. The assessed data indicate that either of the PC salts through their modes of action, could be useful as adjunct therapeutic treatment of crystal associated OA.

show abstract

“…Such Ca-O = C(OH) coordination modes are rare [47,48]. The bridging -PO2À 3 tetrahedral and the CaO 7 polyhedra are arranged in a zigzag chain configuration.…”

mentioning

confidence: 99%

Structural Mapping of Hybrid Metal Phosphonate Corrosion Inhibiting Thin Films

Papadaki

Demadis

2009

Comments on Inorganic Chemistry

Self Cite

View full text Add to dashboard Cite

The constant growth in the area of metal phosphonate materials is exemplified with rich chemistry and a variety of applications. From the multitude of subjects related to metal phosphonates, we have decided to focus on metal phosphonate coordination polymers as corrosion inhibitors in the present Comment. A plethora of metal phosphonate organic-inorganic polymeric hybrid materials have been synthesized, structurally characterized, and evaluated for their anticorrosion properties for the protection of carbon steels. These materials are composed of a metal ion (usually Zn 2þ , Ca 2þ , Sr 2þ , Ba 2þ , etc.) and polyphosphonate ligands such as AMP (amino-tris-(methylenephosphonate) and HDTMP (hexamethylenediaminetetrakis(methylenephosphonate), or carboxyphosphonate ligands, such as PBTC (2-phosphonobutane-1,2,4-tricarboxylate) and HPAA (hydroxyphosphonoacetate). Their corrosion inhibition performance has been evaluated and some interesting conclusions are drawn relating molecular structure to inhibitory activity.

show abstract

A Crystallographically Characterized Nine-Coordinate Calcium−Phosphocitrate Complex as Calcification Inhibitor in Vivo

Cited by 41 publications

References 23 publications

Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

Phosphocitrate, A Potential Therapeutic Agent for Calcium Crystal Deposition Diseases

Structural Mapping of Hybrid Metal Phosphonate Corrosion Inhibiting Thin Films

Contact Info

Product

Resources

About